Table 1.
Demographic and Baseline Characteristics
| Parameter | CCH-aaes (n = 424) | Placebo (n = 419) |
|---|---|---|
| Mean age ± SD, y (range) | 47.8 ± 10.5 (20–78) | 45.8 ± 10.5 (18–72) |
| Age group, n (%), y | ||
| <35 | 46 (10.8) | 61 (14.6) |
| 35–44 | 106 (25.0) | 122 (29.1) |
| 45–64 | 248 (58.5) | 221 (52.7) |
| ≥65 | 24 (5.7) | 15 (3.6) |
| Race, n (%) | ||
| White | 336 (79.2) | 325 (77.6) |
| Black | 76 (17.9) | 75 (17.9) |
| Other | 12 (2.8) | 19 (4.5) |
| BMI category, n (%) | ||
| Underweight/normal (<25 kg/m2) | 81 (19.1) | 84 (20.1)* |
| Overweight (25 to <30 kg/m2) | 143 (33.7) | 123 (29.4)* |
| Obese (≥30 kg/m2) | 200 (47.2) | 211 (50.5)* |
| Fitzpatrick scale category, n (%) | ||
| I (pale white) | 11 (2.6) | 12 (2.9) |
| II (fair) | 124 (29.2) | 102 (24.3) |
| III (darker white) | 119 (28.1) | 139 (33.2) |
| IV (light brown) | 93 (21.9) | 82 (19.6) |
| V (brown) | 48 (11.3) | 45 (10.7) |
| VI (dark brown) | 29 (6.8) | 39 (9.3) |
| Baseline CR-PCSS level, n (%)† | ||
| 3 (moderate) | 257 (60.6) | 259 (61.8) |
| 4 (severe) | 167 (39.4) | 160 (38.2) |
| Baseline PR-PCSS level, n (%)† | ||
| 3 (moderate) | 179 (42.2) | 168 (40.1) |
| 4 (severe) | 245 (57.8) | 251 (59.9) |
*Data missing for one patient in the placebo group (n = 418).
†Target buttock.